IQ Medical and Richter announce the sale and purchase of Giskit MD B.V. 20/07/2023 Rotterdam, the Netherlands and Budapest, Hungary – 20 July 2023 – Gedeon Richter Plc. (“Richter”) and IQ Medical Ventures B.V.... Read more Transparency Report 2022 11/07/2023 As a member of Polski Związek Pracodawców Przemysłu Farmaceutycznego (PZPPF) and Medicine for Europe, Gedeon Richter Polska Sp. z o.o.... Read more U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder 19/12/2022 Approval marks fourth indication for VRAYLAR®, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major... Read more Richter Announces Submission to European Medicines Agency for Type II Variation Application for RYEQO® for the Treatment of Endometriosis 25/10/2022 Budapest, Hungary – 25 October 2022 – Gedeon Richter Plc. (“Richter”) today announced that it has submitted a Type II... Read more Allergan and Richter Announce Positive Topline Results from Phase III Study of Cariprazine for the Treatment of Bipolar I Depression 15/01/2018 Primary endpoint was met in the study evaluating patients with acute bipolar I depression treated with cariprazine 1.5 mg and 3... Read more Richter announces the acquisition of a minority equity stake in Prima-Temp and a related licensing agreement 21/11/2017 Boulder, Colorado, USA – Budapest, Hungary – November 2017 – Gedeon Richter Plc. (“Richter”) today announced that it has entered into... Read more Richter signed a licensing agreement with Pharmanest to commercialize its proprietary pain relief product for gynaecological use in certain territories 19/10/2017 Budapest, Stockholm – 12 October 2017 - Gedeon Richter Plc. (‘Richter’) and Pharmanest AB (‘Pharmanest’) today announced that Richter will commercialise... Read more Gedeon Richter took part in 11th „Run for New Life” edition. 28/09/2017 Last Sunday (24th of September) Gedeon Richter participated in an activity that promotes the idea of transplantation, called “Run for... Read more European Commission approved Reagila® (cariprazine) for the treatment of schizophrenia 24/07/2017 Budapest, Hungary – 19 July 2017 – Gedeon Richter Plc. (“Richter”) announces that the European Commission (EC) has granted marketing... Read more European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia 19/05/2017 Budapest, Hungary – 19 May 2017 – Gedeon Richter Plc. (“Richter”) announces that the Committee for Medicinal Products for Human... Read more
IQ Medical and Richter announce the sale and purchase of Giskit MD B.V. 20/07/2023 Rotterdam, the Netherlands and Budapest, Hungary – 20 July 2023 – Gedeon Richter Plc. (“Richter”) and IQ Medical Ventures B.V.... Read more
Transparency Report 2022 11/07/2023 As a member of Polski Związek Pracodawców Przemysłu Farmaceutycznego (PZPPF) and Medicine for Europe, Gedeon Richter Polska Sp. z o.o.... Read more
U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder 19/12/2022 Approval marks fourth indication for VRAYLAR®, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major... Read more
Richter Announces Submission to European Medicines Agency for Type II Variation Application for RYEQO® for the Treatment of Endometriosis 25/10/2022 Budapest, Hungary – 25 October 2022 – Gedeon Richter Plc. (“Richter”) today announced that it has submitted a Type II... Read more
Allergan and Richter Announce Positive Topline Results from Phase III Study of Cariprazine for the Treatment of Bipolar I Depression 15/01/2018 Primary endpoint was met in the study evaluating patients with acute bipolar I depression treated with cariprazine 1.5 mg and 3... Read more
Richter announces the acquisition of a minority equity stake in Prima-Temp and a related licensing agreement 21/11/2017 Boulder, Colorado, USA – Budapest, Hungary – November 2017 – Gedeon Richter Plc. (“Richter”) today announced that it has entered into... Read more
Richter signed a licensing agreement with Pharmanest to commercialize its proprietary pain relief product for gynaecological use in certain territories 19/10/2017 Budapest, Stockholm – 12 October 2017 - Gedeon Richter Plc. (‘Richter’) and Pharmanest AB (‘Pharmanest’) today announced that Richter will commercialise... Read more
Gedeon Richter took part in 11th „Run for New Life” edition. 28/09/2017 Last Sunday (24th of September) Gedeon Richter participated in an activity that promotes the idea of transplantation, called “Run for... Read more
European Commission approved Reagila® (cariprazine) for the treatment of schizophrenia 24/07/2017 Budapest, Hungary – 19 July 2017 – Gedeon Richter Plc. (“Richter”) announces that the European Commission (EC) has granted marketing... Read more
European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia 19/05/2017 Budapest, Hungary – 19 May 2017 – Gedeon Richter Plc. (“Richter”) announces that the Committee for Medicinal Products for Human... Read more
Allergan and Richter Announce Positive Topline Results from Phase III Study of Cariprazine for the Treatment of Bipolar I Depression 15/01/2018 Primary endpoint was met in the study evaluating patients with acute bipolar I depression treated with cariprazine 1.5 mg and 3... Czytaj Więcej
European Commission approved Reagila® (cariprazine) for the treatment of schizophrenia 24/07/2017 Budapest, Hungary – 19 July 2017 – Gedeon Richter Plc. (“Richter”) announces that the European Commission (EC) has granted marketing... Czytaj Więcej
European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia 19/05/2017 Budapest, Hungary – 19 May 2017 – Gedeon Richter Plc. (“Richter”) announces that the Committee for Medicinal Products for Human... Czytaj Więcej
Richter announces the acquisition of a minority equity stake in Prima-Temp and a related licensing agreement 21/11/2017 Boulder, Colorado, USA – Budapest, Hungary – November 2017 – Gedeon Richter Plc. (“Richter”) today announced that it has entered into... Czytaj Więcej
Richter signed a licensing agreement with Pharmanest to commercialize its proprietary pain relief product for gynaecological use in certain territories 19/10/2017 Budapest, Stockholm – 12 October 2017 - Gedeon Richter Plc. (‘Richter’) and Pharmanest AB (‘Pharmanest’) today announced that Richter will commercialise... Czytaj Więcej
Gedeon Richter took part in 11th „Run for New Life” edition. 28/09/2017 Last Sunday (24th of September) Gedeon Richter participated in an activity that promotes the idea of transplantation, called “Run for... Czytaj Więcej
Richter announces the acquisition of Finox Holding 30/06/2016 30 June 2016 Richter announces the acquisition of Finox Holding for a consideration of CHF190 million. • Finox Holding, a... Czytaj Więcej
Gedeon Richter Plc to further expand its biotechnology plant in Debrecen, which has a cutting edge technology, unique in the region 10/03/2016 Budapest, 10 March 2016 – Gedeon Richter Plc. will spend HUF 15 billion on an investment project to expand its... Czytaj Więcej